284 related articles for article (PubMed ID: 28691194)
1. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
2. Acute generalized exanthematous pustulosis associated with ipilimumab and nivolumab.
Page B; Borradori L; Beltraminelli H; Yawalkar N; Hunger RE
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):e256-e257. PubMed ID: 28430376
[No Abstract] [Full Text] [Related]
3. Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
Hwang SJ; Carlos G; Wakade D; Sharma R; Fernandez-Penas P
Melanoma Res; 2016 Aug; 26(4):417-20. PubMed ID: 27031538
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
5. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
6. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
7. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
8. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
Donaldson M; Owen JL; Choi JN
JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007
[No Abstract] [Full Text] [Related]
9. [Treating metastatic melanoma: Risk management].
Lebbe C; Robert C
Ann Dermatol Venereol; 2017 Jan; 144(1):3-5. PubMed ID: 28063593
[No Abstract] [Full Text] [Related]
10. Bullous pemphigoid induced by pembrolizumab in a patient with advanced melanoma expressing collagen XVII.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Oct; 44(10):e240-e241. PubMed ID: 28677843
[No Abstract] [Full Text] [Related]
11. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
12. Antiphospholipid Syndrome Following Pembrolizumab Treatment of Stage IIIB Unresectable Melanoma.
Sanchez A; Montaudie H; Bory P; Belgodere X; Passeron T; Lacour JP; Picard A
JAMA Dermatol; 2018 Nov; 154(11):1354-1356. PubMed ID: 30326507
[No Abstract] [Full Text] [Related]
13. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.
Acaba-Berrocal LA; Lucio-Alvarez JA; Mashayekhi A; Ho AC; Dunn JP; Shields CL
JAMA Ophthalmol; 2018 Oct; 136(10):1205-1207. PubMed ID: 30054605
[No Abstract] [Full Text] [Related]
14. A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma.
Igari S; Yamamoto M; Kikuchi N; Ohtsuka M; Yamamoto T
An Bras Dermatol; 2024; 99(3):450-451. PubMed ID: 38307808
[No Abstract] [Full Text] [Related]
15. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
16. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
17. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab (Keytruda°) and metastatic or inoperable melanoma.
Prescrire Int; 2017 May; 26(182):118-119. PubMed ID: 30730667
[No Abstract] [Full Text] [Related]
19. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
20. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
Shao K; McGettigan S; Elenitsas R; Chu EY
J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
